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Abstract
Background: Gold nanoparticles are widely used in consumer products, including cosmetics, food packaging,
beverages, toothpaste, automobiles, and lubricants. With this increase in consumer products containing gold
nanoparticles, the potential for worker exposure to gold nanoparticles will also increase. Only a few studies have
produced data on the in vivo toxicology of gold nanoparticles, meaning that the absorption, distribution,
metabolism, and excretion (ADME) of gold nanoparticles remain unclear.
Results: The toxicity of gold nanoparticles was studied in Sprague Dawley rats by inhalation. Seven-week-old rats,
weighing approximately 200 g (males) and 145 g (females), were divided into 4 groups (10 rats in each group):
fresh-air control, low-dose (2.36 × 10
4 particle/cm
3, 0.04 μg/m
3), middle-dose (2.36 × 10
5 particle/cm
3, 0.38 μg/m
3),
and high-dose (1.85 × 10
6 particle/cm
3, 20.02 μg/m
3). The animals were exposed to gold nanoparticles (average
diameter 4-5 nm) for 6 hours/day, 5 days/week, for 90-days in a whole-body inhalation chamber. In addition to
mortality and clinical observations, body weight, food consumption, and lung function were recorded weekly. At
the end of the study, the rats were subjected to a full necropsy, blood samples were collected for hematology and
clinical chemistry tests, and organ weights were measured. Cellular differential counts and cytotoxicity
measurements, such as albumin, lactate dehydrogenase (LDH), and total protein were also monitored in a cellular
bronchoalveolar lavage (BAL) fluid. Among lung function test measurements, tidal volume and minute volume
showed a tendency to decrease comparing control and dose groups during the 90-days of exposure. Although no
statistically significant differences were found in cellular differential counts, histopathologic examination showed
minimal alveoli, an inflammatory infiltrate with a mixed cell type, and increased macrophages in the high-dose rats.
Tissue distribution of gold nanoparticles showed a dose-dependent accumulation of gold in only lungs and
kidneys with a gender-related difference in gold nanoparticles content in kidneys.
Conclusions: Lungs were the only organ in which there were dose-related changes in both male and female rats.
Changes observed in lung histopathology and function in high-dose animals indicate that the highest
concentration (20 μg/m
3) is a LOAEL and the middle concentration (0.38 μg/m
3) is a NOAEL for this study.
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Introduction
Metallic gold (Au°) is arguably considered to be the least
corrosive and most biologically inert of all metals [1].
However, that does not mean Au° has been shown to be
completely inert in mammals. Human exposure to Au°
is common. Much of the earth’s population has
prolonged dermal contact to metallic gold in the form
of jewelry and allergic contact dermatitis (ACD) has
been documented as a result of exposure to dental
restorations, gold jewelry, and use of gold in food [2-5].
The ingestion of gold-containing liquor beverages has
resulted in allergic-type reactions similar to those seen
after gold-allergic individuals are exposed to gold
through medications or jewelry [3]. * Correspondence: u1670916@chollian.net
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human skin biopsies taken from areas of prolonged con-
tact with the metal, such as rings and jewelry, confirm-
ing absorption of the solubilized metal even though
intact stratum corneum. Skin samples taken from
beneath the wedding bands of normal individuals ranged
from 0.07 to 0.09 μg of gold per gram of dry weight [6].
Metallic gold can be gradually dissolved by thiol-
containing molecules such as cysteine, penicillamine,
and glutathione to yield gold (I) complexes [6]. It is pos-
sible that the more reactive Au
+ and Au
3+ species could
be a source of the toxicity attributed to Au° [3]. Addi-
tionally, metallic gold used in jewelry and prostheses is
ordinarily alloyed with other metals; even high-carat
yellow gold contains minute quantities of copper and
silver, while low-carat gold contains these metals plus
zinc and nickel [1].
Gold nanoparticles are widely used in consumer pro-
ducts, including cosmetics, food packaging, beverages,
toothpaste, automobiles, and air handling units. Among
1015 consumer nanotechnology-based products, nano-
gold-based products rank sixth out of 28 products [7].
In addition, many new nano-gold-based biomedical
products are being developed for drug delivery, cancer
therapy, diagnostic devices, and biosensing. With this
increase in consumer products containing gold nanopar-
ticles, the potential for worker exposure to gold nano-
particles will also increase, which has prompted (in part)
a US NTP study of gold nanoparticles [8]. Only a few
studies have produced data on the in vivo toxicology of
gold nanoparticles, meaning that the absorption, distri-
bution, metabolism, and excretion (ADME) of gold
nanoparticles remain unclear. This is partially due to
the high price of gold in long-term in vivo studies. The
present subchronic 90-day inhalation toxicity study was
designed to identify possible adverse effects and deter-
m i n eaL O A E Lo rN O A E L .T h es t u d yw a sd e s i g n e d
according to test guideline 413 from the Organization
for Economic Cooperation and Development (OECD)
[9], and to comply with Good Laboratory Practices
(GLPs). In contrast to silver nanoparticles that are
known to be ionized in biological media, gold nanoparti-
cles are not normally ionized in biological media. Thus,
inhalation exposure to gold nanoparticles provides the
potential to separate the behavior of nanoparticles as
particles from chemical effects.
Materials and methods
Generation of gold nanoparticles
Gold nanoparticles were generated as described in pre-
vious reports [10-13], and the rats exposed in a whole-
body-type exposure chamber (1.3 m
3,D u s t u r b o ,S e o u l ) .
The generation system consisted of a small ceramic hea-
ter connected to an AC power supply and housed
within a quartz tube case. The heater dimensions were
50 × 5 × 1.5 mm
3, and a surface temperature of about
1500°C within a local heating area of 5 × 10 mm
2 was
achieved in about 10 seconds [12]. For long-term test-
ing, the source material (about 700 mg of 24 ct gold)
was positioned at the highest temperature point. The
quartz tube case was 70 mm in diameter and 200 mm
long. Clean (dry and filtered) air was used as the
carrier gas, and the gas flow maintained at 30.0 L/min
(Re = 572, laminar flow regime) using a mass flow con-
troller (MFC, AERA, FC-7810CD-4V, Japan) [10,11].
This generator has already been shown to generate
nanoparticles from 1.8 to 6.1 nm (below 10 nm) in dia-
meter that do not agglomerate in air. XRD analysis
using an X-ray diffractometer with CuK2 radiation pre-
viously showed that the particles generated are metallic
gold, not gold oxides [13]. In the current study, the sys-
tem produced different concentrations of nanoparticles
(high, middle, and low) in three separate chambers. For
the high-concentration chamber, the nanoparticle
generator was operated at 45 L/min (liters per minute)
and mixed with 200 L/min of clean ambient air. A por-
tion of the high nanoparticle concentration was then
diverted to the middle-concentration chamber using an
MFC for the first dilution (1.49 ± 0.06 L/min, mean ±
S.E.), and a portion of the middle nanoparticle concen-
tration then diverted to the low-concentration chamber
using a second MFC (14.94 ± 0.02 L/min).
Monitoring of inhalation chamber and analysis
of gold nanoparticles
In each chamber, nanoparticle distribution in terms of size
was measured directly in real-time using a differential
mobility analyzing system (DMAS); combining a differen-
tial mobility analyzer (Short type-DMA, 4220, HCT Co.,
Ltd. Korea, range 2-150 nm) and condensation particle
counter (CPC, 4312, HCT Co., Ltd. Korea, 0-10
8/cm
3
detection range). The nanoparticles were measured using
sheath air at 5 L/min and polydispersed aerosol air at
1 L/min for the DMA and CPC, respectively.
The control chamber was supplied with HEPA-filtered
fresh air. Particle concentration in the fresh-air control
chamber was measured using a particle sensor (4123,
HCT Co., Ltd. Korea) that consisted of two channels;
300-1000 nm and over 1000 nm, to verify the perfor-
mance of the HEPA filters. Previous studies have shown
that the control chamber contains negligible nanoparti-
cles if the HEPA filter is functioning correctly [14,15].
Transmission Electron Microscopy
T h ef i l t e r su s e dt os a m p l et h ef u m ep a r t i c l e sw e r e
coated with carbon, mounted on an electron microscope
grid (200 mesh, Veco, Eerbeek, Holland), and visualized
under a field emission-transmission electron microscope
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800 randomly selected particles collected using a nano-
particle collector (nanoparticle collector, 4650, HCT
Co., Ltd. Korea) were measured at a magnification of
100,000, and the gold particles analyzed using an
energy-dispersive x-ray analyzer (EDX, TM200, Oxford,
UK) at an accelerating voltage of 200 kV.
Animals and Exposure Conditions
Six-week-old male and female, specific-pathogen-free
(SPF) Sprague-Dawley rats (Slc:SD) (originally derived
from the Charles River SD in 1968) were purchased
from SLC (Tokyo, Japan) and acclimated for 1 week
before starting the experiments. During the acclimation
and experimental periods, the rats were housed in poly-
carbonate cages (3 rats per cage) in a room with con-
trolled temperature (23 ± 2°C), humidity (55 ± 7%), and
a 12-h light/dark cycle. The rats were fed a rodent diet
(Harlan Teklab, Plaster International Co., Seoul) and fil-
tered water ad libitum. The 7-week-old rats, weighed
approximately 200 g for the males and 145 g for the
females at the beginning of exposure. The rats were
divided into 4 groups (10 rats in each group/sex): fresh-
air control, low-dose group (target dose, 2.5 × 10
4 parti-
cles/cm
3,1 . 0×1 0
6 nm
2/cm
3 surface area), middle-dose
group (target dose, 2.5 × 10
5 particles/cm
3,6 . 0×1 0
6
nm
2/cm
3 surface area), and high-dose group (target
dose, 1.2-2.8 × 10
6 particles/cm
3,3 . 0×1 0
8 nm
2/cm
3
surface area). The animals were exposed to the gold
nanoparticles for 6 hours/day, 5 days/week, for
13-weeks, and housed in individual wire cages without
food and water during the 6-hour exposure periods. The
animals were examined daily on weekdays for any evi-
dence of exposure-related effects, including respiratory,
dermal, behavioral, nasal, or genitourinary changes sug-
gestive of irritation. Body weights were evaluated at the
time of purchase, at the time of grouping, after one day
of exposure, once a week during exposure, and before
necropsy. The experiment was approved by the KCL
Institutional Animal Care and Use Committee.
Biochemistry and Hematology
At the conclusion of the 90-day experiment, the rats
were 20 wks old. Before necropsy, food was withheld for
24 h and the rats were anesthetized with an overdose of
sodium pentobarbital. Blood was then drawn from the
abdominal aorta, collected in vacutainers, and analyzed
for ALB (albumin), ALP (alkaline phosphatase), Ca (cal-
cium), CHO (cholesterol), CRE (creatinine), gamma-GT
(gamma-glutamyl transpeptidase), GLU (glucose), GOT
(glutamic oxaloacetic transaminase), GPT (glutamic
pyruvic transaminase), IP (inorganic phosphorus), LDH
(lactate dehydrogenase), MG (magnesium), TP (total
protein), UA (uric acid), BUN (blood urea nitrogen),
TBIL (total bilirubin), CK (creatine phosphokinase), Na
(sodium), K (potassium), Cl (chloride), TG (triglyceride),
and A/G (ratio of albumin to globulin) using a biochem-
ical blood analyzer (Hitachi 7180, Hitachi, Japan). The
blood was also analyzed for the WBC (white blood cell
count), RBC (red blood cell count), Hb (hemoglobin
concentration), HTC (hematocrit), MCV (mean corpus-
cular volume), MCH (mean corpuscular hemoglobin),
MCHC (mean corpuscular hemoglobin concentration),
RDW (red cell distribution width), PLT (platelet count),
MPV (mean platelet volume), NE# (number of neutro-
phils), NE% (percent of neutrophils), LY# (number of
lymphocytes), LY% percent of lymphocytes), MO#
(number of monocytes), MO% (percent of monocytes),
EO# (number of eosinophils), EO% (percent of eosino-
phils), BA# (number of basophils), and BA% (percent of
basophils) using a blood cell counter (Hemavet 0950,
CDC Tech., USA).
Erythrocyte aggregation test
To evaluate aggregation of red blood cells or blood
coagulation attributable to the gold nanoparticles, 3.2%
sodium citrate was used for anticoagulation, and the
activated partial thromboplastin time (APPT) and pro-
thrombin time (PT) measured using a blood coagula-
tion analyzer (ACL 7000, Instrumentation Laborato
Co., U.S.A.).
Kidney function test
Since a gender difference in silver accumulation was
previously noted in kidneys [14,15], kidney function was
measured based on the N-acetyl-beta-D-glucosaminidase
(NAG) and protein in the urine using metabolic cages
for 5 rats from each exposure group and the control.
Organ Weights and Histopathology
After collecting blood samples, rats were killed by cervi-
cal dislocation, and all the organs carefully removed,
including the adrenal glands, bladder, testes, ovaries,
uterus, epididymis, seminal vesicle, heart, thymus, thyr-
oid gland, trachea, esophagus, tongue, prostate, lungs,
nasal cavity, kidneys, spleen, liver, pancreas, brain and
olfactory bulb. The organs were then weighed, fixed in a
10% formalin solution containing neutral phosphate-buf-
fered saline, embedded in paraffin, stained with hema-
toxylin and eosin, and examined under light microscopy.
Lung Function Testing
The lung function of four rats from each dose group
was evaluated every week during the 90-day exposure
using a ventilated bias flow whole-body plethysmograph
(WBP) (SFT3816, Buxco Electronics, Sharon, CT) that
consisted of a reference chamber and animal chamber
interconnected by a pressure transducer (MAX1320,
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taken during pulmonary function testing included the
tidal volume (TV, ml), minute volume (MV, ml/min),
respiratory frequency (BPM, breath/min), inspiration
time (Ti, s), expiration time (Te, s), peak inspiration
flow (PIF, ml/s), and peak expiration flow (PEF, ml/s).
After the last 6-hour exposure, the rats were placed in
an animal chamber, left for 40 min to stabilize, and
measurements were taken in the whole-body plethysmo-
graph for 5 minutes.
Bronchoalveolar Lavage (BAL) Cell Evaluation
The same animals that were used for lung function
testing were also subjected to a BAL at the end of the
90-day exposure period. The rats were deeply anesthe-
tized with an overdose of sodium pentobarbital. Blood
was collected from the abdominal aorta and the rats
were then exsanguinated by severing the abdominal
aorta. The lungs were lavaged 14 times with 3 ml ali-
quots of a warm calcium- and magnesium-free phos-
phate buffer solution (PBS), pH 7.4. The samples were
also centrifuged for 7 min at 500 × g and the cell-free
BAL fluid discarded. The cell pellets from all washes for
each rat were then combined, washed, and resuspended
in 1 ml of a phosphate buffered saline (PBS) buffer and
evaluated [16-20]. Total cell numbers were determined
using a hemacytometer. The cells were first smeared
and then stained with the Wright Giemsa Sure Stain
[21] to allow a count of the total number of cells,
macrophages, polymorphonuclear cells (PMNs), and
lymphocytes. BAL levels of total protein, albumin, and
LDH were also measured using a blood biochemical
analyzer (Hitachi 7180, Hitachi, Japan).
Determination of Tissue Gold
After necropsy, samples of the blood (0.5 ml), liver,
lungs, brain, kidneys, and olfactory bulb were analyzed
to determine organ distribution of gold. Care was taken
to avoid contaminating tissues with gold from the fur
and skin of each animal. After wet digestion using a fla-
meless method, the tissue concentrations of gold were
analyzed using an atomic absorption spectrophotometer
equipped with a Zeeman graphite furnace (Perkin Elmer
5100ZL, Zeeman furnace module, USA) based on the
NIOSH 7300 method [22]. The detection limit was 2
ppb and the limit of quantification was 7 ppb.
Statistical analysis
All results are expressed as means ± standard error (SE).
An analysis of variance (ANOVA) test and Duncan’s
multiple range tests were used to compare the body
weights, bronchoalveolar lavage cell distributions, lung
function test parameters, and all other comparisons for
the three dose groups with those for the control rats.
Histopatholgic results were analyzed using a Chi-square
analysis. The level of significance was set at p < 0.05
and p < 0.01.
Results
Gold nanoparticle distribution
Nanoparticle distributions in chambers are shown in
Table 1. For the high-concentration chamber, the
geometric mean diameter (GMD), concentration, and
surface area of the gold nanoparticles measured by the
DMAS were 5.06 nm, 1.85 × 10
6 particles/cm
3, 20.02
μg/m
3, and 3.64 × 10
8 nm
2/cm
3, respectively; for the
middle-concentration chamber were 4.12 nm, 2.36 × 10
5
particles/cm
3,0 . 3 8μg/m
3 and 1.68 × 10
7 nm
2/cm
3,
respectively, and for the low-concentration chamber
were 4.3 nm, 2.36 × 10
4 particles/cm
3,0 . 0 4μg/m
3,a n d
1.9 × 10
6 nm
2/cm
3, respectively. The gold nanoparticles
observed by TEM were spheroid in shape in both non-
aggregated and non-agglomerated forms, with diameters
under 6 nm (Figure 1,A-C). TEM-EDX analysis indicated
that only elemental gold was present (Figure 1D). The
diameters were log normally distributed between 1 and 6
nm, and the CMD (count median diameter) and GSD
were 2.47 nm and 1.42, respectively (Figure 2). The distri-
bution of gold nanoparticles was well maintained during
the 90-day exposure period, as shown in Figure 3.
Animal Observation, Food Consumption,
and Effect on Body and Organ Weights
No significant gross effects were observed during the
90-day exposure period. There was a loss of hair on the
f r o n tl e f tl e go fo n em a l ei nt h eh i g hd o s eg r o u pa t9
weeks and a loss of hair on both front legs of one
female in the high dose group at 12 weeks of exposure.
There was no apparent reason for the loss of hair in
these two animals. In our experience, hair loss in iso-
lated animals is not an unusual event. Examination of
the eyes of control and high-dose animals did not reveal
any effects. Food intake increased in the high-dose male
group when compared to the control (p < 0.05), middle-
dose (p < 0.05), and low-dose (p < 0.01) groups (Figure
4A). Food intake also increased in the low-dose female
group when compared to the control (p < 0.01), middle-
dose (p < 0.01), and high-dose (p < 0.05) groups
(Figure 4B). While there were no significant changes in
the body weights of the male rats (Figure 5A), there was
a significant body weight gain in the low-dose female
group (p < 0.05) when compared to the control, middle-
dose, and high-dose groups after 4 weeks of exposure
(Figure 5B). There was a 0.3 × 0.2 cm white mass in the
right kidney of one rat from the high-dose group. No
significant organ weight changes were observed in either
the male or female rats at the conclusion of the study
(Table 2 and 3).
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Page 4 of 18Table 1 Distribution of gold nanoparticles (mean ± S.E.).
Group Site Diameter
†(nm) Number (particles/cm
3) Surface (nm
2/cm
3) Mass (μg/m
3)
Control 0 0 0 0
Up
a 4.29(1.69) 2.46 × 10
4 ± 2.38 × 10
2 1.96 × 10
6 ± 3.28 × 10
4 0.04 ± 0.00
Low Down
b 4.32(1.64) 2.21 × 10
4 ± 2.98 × 10
2 1.81 × 10
6 ± 4.03 × 10
4 0.04 ± 0.00
Total 4.30(1.67) 2.36 × 10
4 ± 1.90 × 10
2 1.90 × 10
6 ± 2.55 × 10
4 0.04 ± 0.00
Up 4.11(1.35) 2.40 × 10
5 ± 1.98 × 10
3 1.71 × 10
7 ± 2.24 × 10
5 0.38 ± 0.02
Middle Down 4.13(1.41) 2.29 × 10
5 ± 2.59 × 10
3 1.53 × 10
7 ± 2.05 × 10
5 0.38 ± 0.03
Total 4.12(1.38) 2.36 × 10
5 ± 2.32 × 10
3 1.68 × 10
7 ± 1.66 × 10
5 0.38 ± 0.02
Up 4.96(1.77) 1.98 × 10
6 ± 1.85 × 10
4 3.67 × 10
8 ± 6.35 × 10
7 20.14 ± 0.64
High Down 5.20(1.93) 1.66 × 10
6 ± 1.53 × 10
4 3.60 × 10
8 ± 7.51 × 10
6 20.80 ± 0.73
Total 5.06(1.86) 1.85 × 10
6 ± 1.36 × 10
4 3.64 × 10
8 ± 4.85 × 10
6 20.02 ± 0.41
†: GM(GSD)
a: breathing zone,
b: below breathing zone.
Control chamber indicates number of particles passed after HEPA filter
5 nm
A
10 nm
B
50 nm
C D
Figure 1 TEM morphology of gold nanoparticles and EDX spectrometer pattern. (A-C) Field Emission-Transmission Electron Microscope (×
100,000), (D) EDX spectrometer
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Page 5 of 18Figure 2 Distribution of gold nanoparticles. Cumulative median diameter (CMD). A, number concentration; B, cumulative concentration
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Figure 3 Distribution of gold nanoparticle concentrations during 13-week exposure period.
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Page 6 of 18Effects on Hematology and Blood Biochemistry
No significant dose-related differences were observed for
the hematology values (Table 4 and 5) and blood bio-
chemical measurements (Table 6 and 7).
Gold Distribution in Tissue
Increases in gold concentrations in the lung tissue from
the high dose group as compared to controls were sta-
tistically significant (p < 0.01) and increased with dose
in both the males and females (Table 8 and 9). Gold
concentrations in kidneys also increased in a dose
dependent manner with statistical significance (p <
0.01). Interestingly, there was gender-related difference
in gold concentrations in the kidneys (Table 8 and 9),
with female kidneys showing more gold accumulation
than the male kidneys. Apart from the lungs and kid-
neys, no dose-dependent increase of gold nanoparticles
was found in the blood, live r ,o ro l f a c t o r yb u l bf r o m
both the male and female rats. Gold levels in blood
were less than the tissues measured so that any small
amount of contamination of other tissues with blood or
blood contained in tissue was unlikely to greatly
Figure 4 Food intake change during 90-day exposure period. A, male; B, female. (A. a, p < 0.05 high group vs. low group; b, p < 0.01
middle and high groups vs. low group; c, p < 0.01 high group vs. other groups. B. a, p < 0.05 low group vs. other groups; b. p < 0.05 low
group vs. control and middle groups; c, p < 0.01 low group vs. other groups; d, p < 0.05 low group vs. control and high groups)
Figure 5 Body weight changes for rats exposed to gold nanoparticles. A, male; B, female (a, p < 0.05 low group vs. other groups; b, p <
0.05 low group vs. control group)
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Page 7 of 18influence tissue measurements of gold content. There
was a significant increase in gold nanoparticle concen-
tration only in brain tissue from high-dose females
(Table 9).
Pulmonary Inflammation
Total number of cells, alveolar macrophages, polymor-
phonuclear cells (PMN), and lymphocytes in BAL fluid
after 90-days of exposure are shown in Figure 6. When
compared to the control group, there were no signifi-
cant changes in total cell numbers, alveolar macro-
phages, PMN, or lymphocytes of any exposed males.
There was a significant increase in lymphocytes in
middle and high-dose females (Figure 6B). Albumin,
LDH, and total protein in BAL did not increase signifi-
cantly in either male or female rats (data not shown).
Pulmonary Function Testing
Among the pulmonary function test parameters, there
were significant changes in tidal volume and minute
volume during the 90-days of gold nanoparticle expo-
sure (p < 0.01-0.05) (Figures 7,A and 7B and 8,A and
8B). Dose-dependent tidal volume decreases in male rats
led to minute volume decreases in the high-dose ani-
mals. A tendency towards a dose-dependent decrease in
Table 2 Relative organ weights of male rats (% body weight)
GROUP: (mean ± S.E) Control Low Middle High
Body weight 415.08 ± 7.79 (10) 412.81 ± 10.83 (10) 415.93 ± 11.72 (10) 440.81 ± 12.48 (10)
Testis (Left) 0.41 ± 0.01 (8) 0.44 ± 0.02 (10) 0.45 ± 0.01 (10) 0.41 ± 0.02 (8)
Testis (Right) 0.40 ± 0.01 (8) 0.43 ± 0.02 (10) 0.45 ± 0.01 (10) 0.40 ± 0.02 (8)
Kidney (Left) 0.27 ± 0.01 (8) 0.28 ± 0.00 (10) 0.29 ± 0.01 (10) 0.26 ± 0.01 (8)
Kidney (Right) 0.28 ± 0.01 (8) 0.29 ± 0.01 (10) 0.29 ± 0.01 (10) 0.28 ± 0.01 (8)
Spleen 0.17 ± 0.01 (8) 0.17 ± 0.01 (10) 0.17 ± 0.01 (10) 0.17 ± 0.01 (8)
Liver 2.60 ± 0.05 (8) 2.52 ± 0.05 (10) 2.61 ± 0.05 (10) 2.56 ± 0.05 (8)
Adrenal gland (Left) 0.007 ± 0.000 (8) 0.007 ± 0.001 (10) 0.007 ± 0.000 (10) 0.007 ± 0.000 (8)
Adrenal gland (Right) 0.007 ± 0.000 (8) 0.007 ± 0.000 (10) 0.007 ± 0.001 (10) 0.007 ± 0.001 (8)
Heart 0.27 ± 0.01 (8) 0.28 ± 0.00 (10) 0.28 ± 0.01 (10) 0.27 ± 0.00 (8)
Thymus 0.08 ± 0.01 (8) 0.08 ± 0.00 (10) 0.09 ± 0.01 (10) 0.08 ± 0.01 (8)
Lung (Left) 0.12 ± 0.00 (6) 0.12 ± 0.00 (6) 0.11 ± 0.00 (6) 0.11 ± 0.00 (6)
Kung (Right) 0.22 ± 0.00 (6) 0.23 ± 0.00 (6) 0.21 ± 0.00 (6) 0.21 ± 0.00 (6)
Brain 0.49 ± 0.01 (8) 0.51 ± 0.01 (10) 0.51 ± 0.01 (10) 0.47 ± 0.01 (8)
Olfactory bulb 0.017 ± 0.002 (8) 0.027 ± 0.002 (10) 0.023 ± 0.003 (10) 0.022 ± 0.001 (8)
Hypophysis 0.002 ± 0.000 (8) 0.002 ± 0.000 (10) 0.002 ± 0.000 (10) 0.002 ± 0.000 (8)
( ): number of animals
Table 3 Relative organ weights of female rats (% body weight)
GROUP: (mean ± S.E) Control Low Middle High
Body weight 237.53 ± 6.76 (10) 264.88 ± 5.19 (10) 248.82 ± 9.05 (10) 245.26 ± 4.91 (10)
Ovary (Left) 0.020 ± 0.002 (10) 0.021 ± 0.001 (10) 0.019 ± 0.001 (10) 0.020 ± 0.001 (10)
Ovary (Right) 0.021 ± 0.001 (10) 0.021 ± 0.001 (10) 0.021 ± 0.001 (10) 0.021 ± 0.002 (10)
Kidney (Left) 0.29 ± 0.01 (10) 0.28 ± 0.00 (10) 0.30 ± 0.01 (10) 0.29 ± 0.01 (10)
Kidney (Right) 0.30 ± 0.01 (10) 0.29 ± 0.01 (10) 0.30 ± 0.01 (10) 0.29 ± 0.01 (10)
Spleen 0.20 ± 0.01 (10) 0.18 ± 0.01 (10) 0.19 ± 0.01 (10) 0.18 ± 0.01 (10)
Liver 2.42 ± 0.03 (10) 2.43 ± 0.04 (10) 2.54 ± 0.06 (10) 2.44 ± 0.05 (10)
Adrenal gland (Left) 0.013 ± 0.001 (10) 0.013 ± 0.001 (10) 0.012 ± 0.001 (10) 0.013 ± 0.001 (10)
Adrenal gland (Right) 0.013 ± 0.001 (10) 0.013 ± 0.001 (10) 0.012 ± 0.001 (10) 0.015 ± 0.002 (10)
Heart 0.34 ± 0.01 (10) 0.32 ± 0.01 (10) 0.32 ± 0.01 (10) 0.33 ± 0.01 (10)
Thymus 0.12 ± 0.00 (10) 0.14 ± 0.01 (10) 0.12 ± 0.01 (10) 0.13 ± 0.01 (10)
Lung (Left) 0.18 ± 0.03 (6) 0.17 ± 0.03 (6) 0.17 ± 0.02 (6) 0.16 ± 0.00 (6)
Kung (Right) 0.36 ± 0.05 (6) 0.31 ± 0.03 (6) 0.32 ± 0.04 (6) 0.30 ± 0.01 (6)
Brain 0.84 ± 0.02 (10) 0.76 ± 0.02 (10) 0.80 ± 0.03 (10) 0.82 ± 0.02 (10)
Olfactory bulb 0.040 ± 0.003 (10) 0.034 ± 0.002 (10) 0.041 ± 0.002 (10) 0.039 ± 0.002 (10)
Hypophysis 0.005 ± 0.001 (10) 0.005 ± 0.000 (10) 0.006 ± 0.001 (10) 0.006 ± 0.001 (10)
( ): number of animals
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GROUP: (mean ± S.E) Control Low Middle High
WBC
1 (K/μL) 5.17 ± 0.44 (8) 6.42 ± 0.64 (10) 4.80 ± 0.27 (10) 4.67 ± 0.20 (8)
NE
2 (K/μL) 1.56 ± 0.14 (8) 1.67 ± 0.20 (10) 1.41 ± 0.11 (10) 1.41 ± 0.10 (8)
LY
3 (K/μL) 3.36 ± 0.36 (8) 4.41 ± 0.42 (10) 3.11 ± 0.22 (10) 3.06 ± 0.18 (8)
MO
4 (K/μL) 0.24 ± 0.03 (8) 0.32 ± 0.04 (10) 0.27 ± 0.17 (10) 0.19 ± 0.02 (8)
EO
5 (K/μL) 0.005 ± 0.002 (8) 0.018 ± 0.013 (10) 0.006 ± 0.002 (10) 0.014 ± 0.003 (8)
BA
6 (K/μL) 0.000 ± 0.000 (8) 0.008 ± 0.008 (10) 0.000 ± 0.000 (10) 0.003 ± 0.002 (8)
NE
7 (%) 30.72 ± 2.39 (8) 25.71 ± 0.98 (10) 29.553 ± 1.70 (10) 30.28 ± 2.07 (8)
LY
8 (%) 64.45 ± 2.38 (8) 68.97 ± 1.18 (10) 64.52 ± 1.77 (10) 65.39 ± 1.96 (8)
MO
9 (%) 4.71 ± 0.50 (8) 5.05 ± 0.48 (10) 5.78 ± 0.42 (10) 4.00 ± 0.27 (8)
EO
10 (%) 0.10 ± 0.03 (8) 0.20 ± 0.11 (10) 0.15 ± 0.05 (10) 0.30 ± 0.05 (8)
BA
11 (%) 0.15 ± 0.01 (8) 0.08 ± 0.07 (10) 0.01 ± 0.00 (10) 0.03 ± 0.02 (8)
RBC
12 (M/μL) 8.87 ± 0.11 (8) 8.67 ± 0.33 (10) 9.18 ± 0.16 (10) 9.09 ± 0.17 (8)
Hb
13 (g/dL) 17.68 ± 0.23 (8) 17.33 ± 0.18 (10) 18.26 ± 0.24
c (10) 17.91 ± 0.22 (8)
HCT
14 (%) 36.71 ± 1.07 (8) 36.68 ± 0.95 (10) 38.26 ± 0.98 (10) 37.66 ± 1.18 (8)
MCV
15 (fL) 41.35 ± 0.97 (8) 42.30 ± 0.86 (10) 41.65 ± 0.78 (10) 41.46 ± 1.13 (8)
MCH
16 (pg) 19.95 ± 0.34 (8) 20.00 ± 0.25 (10) 19.92 ± 0.36 (10) 19.73 ± 0.28 (8)
MCHC
17 (g/dL) 48.39 ± 1.29 (8) 47.53 ± 1.31 (10) 47.98 ± 1.32 (10) 47.86 ± 1.44 (8)
RDW
18 (%) 20.74 ± 0.94 (8) 21.24 ± 1.08 (10) 21.76 ± 1.09 (10) 20.84 ± 0.97 (8)
PLT
19 (K/μL) 949.88 ± 50.68 (8) 862.70 ± 41.33 (10) 894.30 ± 32.72 (10) 882.38 ± 42.43 (8)
MPV
20 (fL) 6.43 ± 0.09 (8) 6.67 ± 0.12 (10) 6.61 ± 0.11 (10) 6.44 ± 0.16 (8)
( ): number of animals
1, White blood cells; 2, Neutrophils; 3, Lymphocytes; 4, Monocytes; 5, Eosinophils; 6, Basophils; 7, Percent of neutrophils; 8, Percent of lymphocytes; 9, Percent of
monocytes; 10, Percent of eosinophils; 11, Percent of basophils; 12, Red blood cells; 13, Hemoglobin; 14, Hematocrits; 15, Mean corpuscular volume; 16, Mean
corpuscular hemoglobin; 17, Mean corpuscular hemoglobin concentration; 18, Red cell distribution width; 19, Platelet; 20, Mean platelet volume
Table 5 Hematological values for female rats
GROUP: (mean ± S.E) Control Low Middle High
WBC
1 (K/μL) 3.60 ± 0.43 (10) 2.99 ± 0.30 (10) 3.25 ± 0.36 (10) 3.39 ± 0.39 (10)
NE
2 (K/μL) 0.96 ± 0.11 (10) 0.81 ± 0.08 (10) 0.79 ± 0.08 (10) 1.02 ± 0.15 (10)
LY
3 (K/μL) 2.50 ± 0.33 (10) 2.06 ± 0.22 (10) 2.31 ± 0.28 (10) 2.24 ± 0.25 (10)
MO
4 (K/μL) 0.13 ± 0.03 (10) 0.12 ± 0.02 (10) 0.14 ± 0.02 (10) 0.12 ± 0.02 (10)
EO
5 (K/μL) 0.007 ± 0.004 (10) 0.004 ± 0.002 (10) 0.006 ± 0.002 (10) 0.006 ± 0.002 (10)
BA
6 (K/μL) 0.002 ± 0.002 (10) 0.000 ± 0.000 (10) 0.001 ± 0.001 (10) 0.000 ± 0.000 (10)
NE
7 (%) 27.22 ± 2.34 (10) 27.42 ± 1.37 (10) 24.97 ± 1.43 (10) 29.81 ± 1.87 (10)
LY
8 (%) 26.99 ± 2.13 (10) 68.23 ± 1.57 (10) 70.62 ± 1.40 (10) 66.50 ± 1.68 (10)
MO
9 (%) 3.47 ± 0.43 (10) 4.16 ± 0.51 (10) 4.17 ± 0.31 (10) 3.49 ± 0.53 (10)
EO
10 (%) 0.24 ± 0.09 (10) 0.17 ± 0.04 (10) 0.20 ± 0.05 (10) 0.18 ± 0.04 (10)
BA
11 (%) 0.08 ± 0.04 (10) 0.02 ± 0.01 (10) 0.04 ± 0.02 (10) 0.03 ± 0.01 (10)
RBC
12 (M/μL) 8.19 ± 0.09 (10) 7.94 ± 0.15 (10) 8.07 ± 0.05 (10) 7.96 ± 0.11 (10)
Hb
13 (g/dL) 16.99 ± 0.22 (10) 16.70 ± 0.28 (10) 16.74 ± 0.12 (10) 16.61 ± 0.27 (10)
HCT
14 (%) 39.93 ± 0.67 (10) 39.41 ± 0.71 (10) 39.54 ± 0.41 (10) 39.24 ± 0.71 (10)
MCV
15 (fL) 48.82 ± 0.86 (10) 49.70 ± 0.39 (10) 48.99 ± 0.65 (10) 49.30 ± 0.50 (10)
MCH
16 (pg) 20.77 ± 0.29 (10) 21.06 ± 0.22 (10) 20.74 ± 0.18 (10) 20.87 ± 0.19 (10)
MCHC
17 (g/dL) 42.58 ± 0.37 (10) 42.38 ± 0.31 (10) 42.37 ± 0.36 (10) 42.35 ± 0.26 (10)
RDW
18 (%) 22.75 ± 1.22 (10) 22.58 ± 1.27 (10) 22.52 ± 1.10 (10) 23.94 ± 1.34 (10)
PLT
19 (K/μL) 693.10 ± 68.03 (10) 762.70 ± 25.24 (10) 729.00 ± 15.91 (10) 764.90 ± 14.86 (10)
MPV
20 (fL) 6.45 ± 0.15 (10) 6.66 ± 0.17 (10) 6.47 ± 0.14 (10) 6.36 ± 0.20 (10)
( ): number of animals
1, White blood cells; 2, Neutrophils; 3, Lymphocytes; 4, Monocytes; 5, Eosinophils; 6, Basophils; 7, Percent of neutrophils; 8, Percent of lymphocytes; 9, Percent of
monocytes; 10, Percent of eosinophils; 11, Percent of basophils; 12, Red blood cells; 13, Hemoglobin; 14, Hematocrits; 15, Mean corpuscular volume; 16, Mean
corpuscular hemoglobin; 17, Mean corpuscular hemoglobin concentration; 18, Red cell distribution width; 19, Platelet; 20, Mean platelet volume
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Page 9 of 18Table 6 Serum biochemical values for male rats
GROUP: (mean ± S.E) Control Low Middle High
ALB
1 (g/dL) 2.43 ± 0.02 (8) 2.42 ± 0.02 (10) 2.50 ± 0.03 (10) 2.56 ± 0.05 (8)
ALP
2 (IU/L) 286.63 ± 13.86 (8) 299.10 ± 17.32 (10) 332.30 ± 17.13 (10) 292.88 ± 121.40 (8)
CA
3 (mg/dL) 9.18 ± 0.12 (8) 9.09 ± 0.04 (10) 15.02 ± 0.75b (10) 18.93 ± 0.14 (8)
CHO
4 (mg/dL) 68.75 ± 4.69 (8) 69.60 ± 4.76 (10) 69.00 ± 3.44 (10) 77.38 ± 8.66 (8)
CRE
5 (mg/dL) 0.53 ± 0.05 (8) 0.59 ± 0.13 (10) 1.08 ± 0.08b (10) 0.91 ± 0.12 (8)
g-GT
6 (IU/L) 1.38 ± 0.18 (8) 1.10 ± 0.18 (10) 1.10 ± 0.18 (10) 1.25 ± 0.16 (8)
GLU
7 (mg/dL) 158.13 ± 9.34 (8) 175.40 ± 9.56 (10) 188.50 ± 13.55 (10) 162.38 ± 7.81 (8)
GOT
8 (IU/L) 124.25 ± 16.27 (8) 105.10 ± 8.97 (10) 108.60 ± 9.89 (10) 102.13 ± 14.7 (8)
GPT
9 (IU/L) 66.63 ± 14.49 (8) 49.30 ± 2.50 (10) 54.90 ± 4.18 (10) 51.50 ± 6.76 (8)
IP
10 (mg/dL) 6.54 ± 0.31 (8) 6.73 ± 0.24 (10) 6.60 ± 0.20 (10) 6.20 ± 0.23 (8)
LDH
11 (IU/L) 562.63 ± 103.39 (8) 555.50 ± 149.47 (10) 592.40 ± 179.20 (10) 538.88 ± 193.15 (8)
MG
12 (mg/dL) 2.04 ± 0.04 (8) 2.12 ± 0.05 (10) 2.05 ± 0.05 (10) 2.03 ± 0.05 (8)
TP
13 (g/dL) 6.00 ± 0.07 (8) 5.92 ± 0.02 (10) 6.11 ± 0.05 (10) 6.25 ± 0.09 (8)
UA
14 (mg/dL) 1.24 ± 0.21 (8) 1.39 ± 0.10 (10) 1.62 ± 0.26 (10) 1.04 ± 0.10 (8)
BUN
15 (mg/dL) 15.88 ± 0.65 (8) 16.86 ± 0.47 (10) 16.33 ± 0.48 (10) 15.11 ± 0.37 (8)
TBIL
16 (mg/dL) 0.013 ± 0.004 (8) 0.008 ± 0.005 (10) 0.001 ± 0.008 (10) 0.010 ± 0.008 (8)
TG
17 (mg/dL) 37.25 ± 6.87 (8) 40.60 ± 9.24 (10) 38.80 ± 6.00 (10) 41.75 ± 5.54 (8)
CK
18 (IU/L) 543.88 ± 77.39 (8) 1001.20 ± 213.75 (10) 759.70 ± 146.20 (10) 419.13 ± 125.29 (8)
Na
19 (mmol/L) 129.13 ± 0.35 (8) 129.30 ± 0.52 (10) 128.50 ± 0.56 (10) 132.13 ± 2.07 (8)
K
20 (mmol/L) 2.80 ± 0.07 (8) 3.02 ± 0.10 (10) 3.21 ± 0.15 (10) 2.80 ± 0.10 (8)
Cl
21 (mmol/L) 97.25 ± 0.31 (8) 97.70 ± 0.21 (10) 97.10 ± 0.35 (10) 99.75 ± 1.49 (8)
( ): number of animals
1, Albumin; 2, Alkaline phosphatase; 3, Calcium; 4, Cholesterol; 5, Creatinine; 6, Gamma glutamyl transpeptidase; 7, Glucose; 8, Glutamic oxalacetic transaminase;
9, Glutamic pyruvic transaminase; 10, Inorganic phosphorus; 11, Lactate Dehydrogenase; 12, Magnesium; 13, Total protein; 14, Uric acid; 15, Blood urea nitrogen;
16, Total bilirubin; 17, Triglyceride; 18, Creatine Kinase; 19, Sodium; 20, Potassium; 21, Chloride
Table 7 Serum biochemical values for female rats
GROUP: (mean ± S.E) Control Low Middle High
ALB
1 (g/dL) 2.77 ± 0.07 (10) 2.76 ± 0.08 (10) 3.18 ± 0.11 (10) 2.85 ± 0.06 (10)
ALP
2 (IU/L) 223.20 ± 16.90 (10) 200.80 ± 22.94 (10) 167.70 ± 9.59 (10) 227.20 ± 13.71 (10)
CA
3 (mg/dL) 10.02 ± 0.10 (10) 10.10 ± 0.14 (10) 10.36 ± 0.17 (10) 10.29 ± 0.19 (10)
CHO
4 (mg/dL) 89.60 ± 4.49 (10) 96.90 ± 4.66 (10) 105.20 ± 5.59 (10) 92.70 ± 5.18 (10)
CRE
5 (mg/dL) 0.78 ± 0.04 (10) 0.89 ± 0.04 (10) 0.89 ± 0.07 (10) 0.85 ± 0.03 (10)
g-GT
6 (IU/L) 0.10 ± 0.10 (10) 0.20 ± 0.13 (10) 0.00 ± 0.00 (10) 0.40 ± 0.22 (10)
GLU
7 (mg/dL) 134.70 ± 5.24 (10) 143.30 ± 4.82 (10) 154.50 ± 8.04 (10) 135.90 ± 5.23 (10)
GOT
8 (IU/L) 69.00 ± 2.21 (10) 141.20 ± 48.60 (10) 77.40 ± 4.96 (10) 82.30 ± 5.17 (10)
GPT
9 (IU/L) 33.80 ± 1.13 (10) 64.20 ± 15.61 (10) 40.60 ± 2.85 (10) 41.60 ± 2.63 (10)
IP
10 (mg/dL) 5.66 ± 0.23 (10) 5.64 ± 0.49 (10) 5.58 ± 0.40 (10) 5.55 ± 0.29 (10)
LDH
11 (IU/L) 180.40 ± 27.93 (10) 254.90 ± 49.86 (10) 222.70 ± 22.46 (10) 216.40 ± 30.50 (10)
MG
12 (mg/dL) 2.06 ± 0.04 (10) 2.04 ± 0.04 (10) 2.13 ± 0.07 (10) 2.03 ± 0.04 (10)
TP
13 (g/dL) 6.20 ± 0.09 (10) 6.07 ± 0.17 (10) 6.76 ± 0.18 (10) 6.40 ± 0.13 (10)
UA
14 (mg/dL) 1.07 ± 0.11 (10) 1.22 ± 0.09 (10) 1.14 ± 0.06 (10) 0.99 ± 0.08 (10)
BUN
15 (mg/dL) 17.86 ± 0.74 (10) 18.08 ± 0.61 (10) 18.99 ± 0.90 (10) 17.52 ± 0.87 (10)
TBIL
16 (mg/dL) 0.005 ± 0.015 (10) 0.009 ± 0.013 (10) 0.020 ± 0.005 (10) 0.024 ± 0.005 (10)
TG
17 (mg/dL) 8.50 ± 1.28 (10) 9.40 ± 0.93 (10) 11.20 ± 1.83 (10) 6.90 ± 0.57 (10)
CK
18 (IU/L) 269.20 ± 64.71 (10) 265.50 ± 24.99 (10) 341.30 ± 68.11 (10) 212.30 ± 26.38 (10)
Na
19 (mmol/L) 136.50 ± 0.48 (10) 139.20 ± 2.80 (10) 138.90 ± 0.95 (10) 138.50 ± 1.26 (10)
K
20 (mmol/L) 3.69 ± 0.12 (10) 3.56 ± 0.10 (10) 3.62 ± 0.07 (10) 3.48 ± 0.09 (10)
Cl
21 (mmol/L) 102.00 ± 0.33 (10) 103.40 ± 2.05 (10) 103.00 ± 0.86 (10) 102.80 ± 1.17 (10)
( ): number of animals
1, Albumin; 2, Alkaline phosphatase; 3, Calcium; 4, Cholesterol; 5, Creatinine; 6, Gamma glutamyl transpeptidase; 7, Glucose; 8, Glutamic oxalacetic transaminase;
9, Glutamic pyruvic transaminase; 10, Inorganic phosphorus; 11, Lactate Dehydrogenase; 12, Magnesium; 13, Total protein; 14, Uric acid; 15, Blood urea nitrogen;
16, Total bilirubin; 17, Triglyceride; 18, Creatine Kinase; 19, Sodium; 20, Potassium; 21, Chloride
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but was not statistically significant.
Histopathologic Examination
The only significant changes in histopathology occurred
in lungs (Table 10 and 11), where there was minor focal
inflammation with an inflammatory infiltrate of mixed
cell type (lymphocyte/neutrophil/macrophage) were
noted in both treated male and female rats. The
increases were dose-dependent in female rats (Figure 9).
Erythrocyte aggregation and kidney function test
To evaluate changes in red blood cell aggregation or
blood coagulation, erythrocyte aggregation, activated
partial thromboplastin time (APPT), and prothrombin
time (PT) were tested. No significant differences were
found between the control and any treated animals in
APPT or PT (Figure 10,A and 10B). There were no sig-
nificant differences among dose groups in kidney func-
tion as measured based on the NAG and protein in the
urine (Figure 11,A and 11B).
Discussion
To the best of our knowledge, this is the first subchro-
nic 90-day inhalation study using gold nanoparticles to
be reported in the peer-reviewed literature. An impor-
tant aspect of this and predecessor studies from our
laboratory is that the surface of the nanoparticles used
for this exposure were not modified and not oxidized.
There is one previous inhalation (intratracheal instilla-
t i o n )s t u d yw h i c hu s e d1 . 4n ma n d1 8n mp a r t i c l e s
whose surface was ligated with Ph2PC6H4SO3Na [23]
and one 15-day whole body inhalation study which used
citrated 20 nm particles [24].
Interestingly, a recent publication [25] found that col-
loidal gold nanoparticles diluted in ultrapure water were
well-dispersed, while agglomerates were formed when
the diluent was phosphate buffered saline. In that study,
rats were administered 50 nm and 250 nm gold particles
by intratracheal injection. Despite differences in the
degree of agglomeration due to the two diluents, no
major differences in pulmonary and systemic toxicity
markers were observed.
It is possible to calculate a deposited dose in the lung
for this study. The deposited dose is calculated as fol-
lows:
Deposited dose = (minute volume) × (number of minutes of exposure)×
(concentration in air) × (fraction of the dose retained)
I ft h em i n u t ev o l u m eo fm a l ea n df e m a l eS p r a g u e -
Dawley rats in a subchronic study is 0.19 and 0.15 L/min,
respectively [26] and the fraction of the dose deposited
for particles less than 10 nm in diameter is 0.8 [27], then
the deposited dose to the lung would be 0.14 μg, 1.35 μg
and 71.1 μg for the low, middle, and high dose males,
respectively. For the low, middle, and high dose females,
the deposited dose to the lung would be 0.11 μg, 1.07 μg
and 56.2 μg, respectively. For comparison purposes and
using the same assumptions, we can calculate deposited
dose to the lung from our previously reported subchronic
inhalation study of 18-19 nm silver particles [14]. The
deposited dose to the lung for the silver study would be
170 μg, 470 μg and 1800 μg for the low, middle, and high
dose males, respectively. For the low, middle, and high
Table 8 Gold distribution in tissue of male rats after 90-day gold nanoparticle exposure.
GROUP: (mean ± S.E) Control Low Middle High
Lungs (ng/g) 14.33 ± 1.25 (5) 17.41 ± 1.49 (5) 36.88 ± 1.69 (5) 2191.77 ± 222.59
a (5)
Liver (ng/g) 13.58 ± 0.69 (5) 13.72 ± 1.26 (5) 13.77 ± 1.62 (5) 14.34 ± 1.56 (5)
Kidneys (ng/g) 18.56 ± 1.37 (5) 21.19 ± 0.75 (5) 23.13 ± 1.33 (5) 43.24 ± 2.15
a (5)
Brain (ng/g) 17.62 ± 1.71 (5) 19.77 ± 0.96 (5) 15.03 ± 1.10 (5) 17.02 ± 0.94 (5)
Olfactory bulb (ng/g) 11.07 ± 3.88 (8) 19.22 ± 3.61 (10) 21.37 ± 3.65 (10) 16.57 ± 3.47 (8)
Blood (ng/ml) 6.93 ± 0.61 (8) 5.75 ± 0.73 (10) 6.41 ± 0.65 (10) 6.86 ± 0.89 (8)
( ): number of animals, a: p < 0.01, high group vs. other groups
Table 9 Gold distribution in tissue of female rats after 90-day gold nanoparticle exposure.
GROUP: (mean ± S.E) Control Low Middle High
Lungs (ng/g) 13.75 ± 0.95 (5) 15.07 ± 2.02 (5) 28.34 ± 1.16 (5) 1960.02 ± 92.80
a (5)
Liver (ng/g) 16.57 ± 3.89 (5) 12.08 ± 2.13 (5) 12.31 ± 1.18 (5) 14.96 ± 1.54 (5)
Kidneys (ng/g) 21.27 ± 0.65 (5) 19.43 ± 0.79 (5) 26.37 ± 0.79 (5) 61.90 ± 3.15
a,** (5)
Brain (ng/g) 19.13 ± 2.31 (5) 18.42 ± 1.07 (5) 17.87 ± 0.86 (5) 22.15 ± 0.75** (5)
Olfactory bulb (ng/g) 23.19 ± 2.45 (10) 20.22 ± 4.35 (10) 23.56 ± 4.15 (10) 22.92 ± 4.07 (10)
Blood (ng/ml) 6.66 ± 0.78 (10) 6.92 ± 1.08 (10) 5.10 ± 0.58 (10) 8.98 ± 1.25 (10)
( ), number of animals; a, p < 0.01 high group vs. other groups; **, p < 0.01 female rats vs. male rats in high group
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140 μg, 370 μg and 1400 μg, respectively. Thus, the high
deposited dose in our subchronic gold study is about 40%
by weight of the low deposited dose in our subchronic
silver study.
There is considerable uncertainty in the fraction of the
dose retained for particles less than 10 nm in diameter as
opposed to the fraction of the dose deposited as used in
the calculation above. It is likely that the retained dose is
significantly different than 0.8 due to such factors as trans-
location to other organs and species-specific deposition
patterns. The reader is referred to more comprehensive
discussions of retention of nanoparticles and deposition
modeling in human and animal models [28-32].
Figure 6 Number of total cells, macrophages, PMN, and lymphocytes in rats exposed to gold nanoparticles. A, male; B, female. (B. a, p <
0.05 middle and high groups vs. control and low groups)
Figure 7 Lung function test of male rats after gold nanoparticle exposure. A: Tidal volume (mL), B: Minute volume (mL/min) (A. a, p < 0.05,
high group vs. control and low groups; b, p < 0.05, middle and high groups vs. low group; c, p < 0.05, high group vs. control and middle
groups; d, p < 0.01, high group vs. low and middle groups; e, p < 0.05, high group vs. other groups; f, p < 0.01, control and high groups vs.
middle group; g, p < 0.05, control and high groups vs. low group; h, p < 0.05, high group vs. low group; i, p < 0.05, high group vs. control
group. B. a, p < 0.01, control group vs. other groups; b, p < 0.01, high group vs. control and low groups; c, p < 0.05, low and high groups vs.
control group; d, p < 0.05, low group vs. control and middle groups; e, p < 0.05, high group vs. middle group; f, p < 0.01, low and high groups
vs. control and middle groups; g, p < 0.01, middle group vs. other groups; h, p < 0.05, middle group vs. low and high groups)
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component of exposure; that of ingestion since particles
accumulate on the skin and fur. It is well known that
rats clean skin and fur by licking, thus introducing parti-
cles to the gastrointestinal tract. For particles of gold
larger than the nanometer range, it is generally assumed
that the particles are not absorbed. Little is known
about gastro-intestinal absorption of gold nanoparticles,
but there are reports on the permeability of rat intestine
to colloidal gold nanoparticles. Sonavane et al. [33] stu-
died movements of 15, 102, and 198 nm colloidal gold
particles across intestine in vitro. Fifteen nm particles
were shown to cross the intestine more readily than 102
or 198 nm particles. The permeation of these particles
through rat intestine was higher than rat skin. Hillyer et
al. [34] studied absorption of 4, 10, 28, and 58 colloidal
gold nanoparticles fed to mice. In general, smaller
particles were absorbed more readily and corresponding
tissue levels were higher. The applicability of this data
to whole body inhalation is not apparent because of the
colloidal nature of the tested particles [33,34]. Clearly,
quantitative in vivo data on the absorption of unmodi-
fied gold nanoparticles in the rat would be of great
value in determining the relative contribution of gastro-
intestinal absorption to the accumulation of gold from
nanoparticles.
Figure 8 Lung function test of female rats after gold nanoparticle exposure. A, Tidal volume (mL); B, Minute volume (mL/min) (A. a,
p < 0.01, control and high groups vs. low and middle groups; b, p < 0.01, middle group vs. other groups; c, p < 0.01, middle group vs. high
group; d, p < 0.05, low group vs. middle group; e, p < 0.01, low group vs. middle and high groups. B. a, p < 0.01, control group vs. middle and
high groups; b, p < 0.01, middle group vs. other groups; c, p < 0.05, high group vs. other groups; d, p < 0.01, high group vs. other groups;
e, p < 0.05, control group vs. other group)
Table 10 Histopathologic observations for male rats.
GROUP: Control Low Middle High
Number of Animals 8 10 10 8
N %N%N% N %
No microscopic findings 8/8 100 10/10 100 6/10 60 5/8 62.5
Abnormality* 0/8 0 0/10 0 4/10 40 3/8 37.5
Liver Inflammation Focal minimum 0/8 0 0/10 0 0/10 0 1/8 12.5
Sign Multifocal minimum 0/8 0 0/10 0 3/10 30 0/8 0
Necrosis Focal minimum 0/8 0 0/10 0 0/10 0 2/8 25
Vacuolation Hepatocellular minimum 0/8 0 0/10 0 1/10 10 1/8 12.5
No microscopic findings 7/8 87.5 10/10 100 10/10 100 5/8 62.5
Lungs Abnormality* 1/8 12.5 0/10 0 0/10 0 3/8 37.5
Sign Inflammation* Focal minimum 1/8 12.5 0/10 0 0/10 0 3/8 37.5
Osseous Metaplasia 0/8 0 0/10 0 0/10 0 1/8 12.5
*, p < 0.05 compared with controls. Abnormality” refers to such changes as inflammation, vacuolization and necrosis upon histopathological examination. One
abnormality is counted even if inflammation and necrosis are present simultaneously.
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Page 13 of 18Table 11 Histopathologic observations for female rats.
GROUP: Control Low Middle High
Number of Animals 10 10 10 10
N%N% N % N %
No microscopic findings 9/10 90 9/10 90 8/10 80 7/10 70
Abnormality 1/10 10 1/10 10 2/10 20 3/10 30
Inflammation Focal minimum 0/10 0 1/10 10 0/10 0 0/10 0
Liver mild 1/10 10 0/10 0 0/10 0 0/10 0
Sign Necrosis Focal minimum 0/10 0 0/10 0 1/10 10 1/10 10
Vacuolization Hepatocellular minimum 0/10 0 0/10 0 1/10 10 2/10 20
mild 0/10 0 0/10 0 0/10 0 1/10 10
No microscopic findings 10/10 100 10/10 100 9/10 90 3/10 30
Lungs Abnormality** 0/10 0 0/10 0 1/10 10 7/10 70
Sign Inflammation** Focal minimum 0/10 0 0/10 0 1/10 10 6/10 60
mild 0/10 0 0/10 0 0/10 0 1/10 10
**, p < 0.01, compared with control. Abnormality” refers to such changes as inflammation, vacuolization and necrosis upon histopathological examination. One
abnormality is counted even if inflammation and necrosis are present simultaneously
Figure 9 Histopathologic findings for lungs.
Sung et al. Particle and Fibre Toxicology 2011, 8:16
http://www.particleandfibretoxicology.com/content/8/1/16
Page 14 of 18Tissue concentrations of gold from control rats have
been reported in several studies [24,35] and tend to be
lower than found in our study (Table 8 and 9). Take-
naka et al. [34] reported gold in control lungs to be 0.07
± 0.003 ng/g and in control blood to be 0.1 ± 0.07 ng/
ml (mean ± SD). Yu et al. [24] reported gold in control
lungs to be 5.50 ± 4.44 ng/g and in control blood to be
5.83 ± 3.02 ng/ml. Yu et al. [24] also reported gold in
control olfactory bulb to be 4.44 ± 4.43 ng/g and in
control brain to be from 4.67 ± 3.63 to 20.27 ± 15.79
ng/g (presumed to be mean ± SD) depending on the
part of the brain analyzed. Because of the low levels of
gold in tissues, the authors cannot rule out the possibi-
lity of contamination of internal tissues from skin or fur.
Mitigating that possibility is previous experience by the
authors in whole-body inhalation studies involving
nanoparticles. Nevertheless, the reader should consider
the possibility for such contamination.
The results of this study indicated that the lungs were
the major target tissue; pulmonary effects included a
decrease in tidal and minute volume and the presence
of mixed inflammatory cell infiltrates. Dose-related
changes in tidal and minute volume tend to be obscured
by changes over time which also occurred in control
animals. In our experience, pulmonary function changes
can reproduce poorly over time because they are depen-
dent on so many variables. The decrease in pulmonary
function following 90-days of gold nanoparticle
Figure 10 Blood coagulation time (seconds) for rats exposed to gold nanoparticles. A, male; B, female. (A. a, p < 0.05 control group vs.
other groups)
Figure 11 Kidney function test after 90-day gold nanoparticle exposure. A, NAG; B, Protein
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Page 15 of 18inhalation in the current study was similar, although
lower, than that reported after 90-days of silver nano-
particle inhalation [14].
In the present study inhaled gold nanoparticles accu-
mulated in a dose-dependent manner in lungs and kid-
neys of both male and female rats (p < 0.01), but not in
liver, blood, and olfactory bulb. This is in contrast to
the study of Yu et al. [24] where rats are exposed to 20
nm gold nanoparticles at a concentration of 2 × 10
6/
cm
3 (mass concentration not reported) for 15 days by
inhalation reported that the particles relocate from
lungs to liver. Exposure in that study for 5 days resulted
in a significant increase of gold in the lungs and olfac-
tory bulb, as detected by ICP-MS; after 15 days of expo-
sure, a significant accumulation of gold was detected in
the lungs, esophagus, tongue, kidneys, aorta, spleen, sep-
tum, heart, and blood. Five or 15 days of inhalation
exposure to gold nanoparticles resulted in a slight accu-
mulation of gold in liver and a minimal increase the
gold content of the olfactory bulb indicating a small but
significant translocation from lung to blood after 15
days of exposure. Takenaka et al. [35] exposed rats to
16 nm gold particles at a concentration of 4 × 10
5/cm
3
(88 μg/m
3) for 6 hours and then serially sacrificed ani-
mals at 0, 1, 4, and 7 days. These data also indicate a
small but significant translocation from lung to blood.
The lack of significant increase in gold concentration
in the olfactory bulb in our study is interesting with
regard to findings in previously reported studies of
shorter duration, particularly those of Yu et al. [24].
They showed a small but significant increase in the con-
centration of gold in the olfactory bulb and parts of the
brain. The reason for the differences between our study
and that of Yu et al. [24] are not apparent, but could be
related to the surface composition of the nanoparticle
itself, duration of exposure or the higher concentrations
of gold in found in the olfactory bulbs of control
animals.
The results of our 90-day study are not consistent
with data from studies of nanoparticles of different com-
position and duration and stand in contrast to Elder et
al. [36] using inhaled Mn oxides nanoparticles and Bala-
subramanian et al. [37] using intravenously injected gold
nanoparticles. Elder et al. found that when rats inhaled
manganese oxide particles (agglomerates measured 30
nm in diameter with primary particles of 3-8 nm) for 12
days, the particles accumulated in the olfactory bulb
[36]. It is not clear if the differences between our study
and that of Elder et al. are due to exposure duration,
particle size, or solubility. Balasubramanian et al. [37]
reported that a single intravenous injection of gold
nanoparticles yielded a large amount of gold in
the olfactory bulb (up to 72.2 ng/g) two months after
intravenous gold nanoparticle injection. A similar
comparative distribution between intravenous injection
and intratracheal instillation was also observed in a
s t u d yb yS e m m l e r - B e h n k ee t . al. [23]. Perhaps this con-
currence of distribution is related to the fact that both
intravenous injection and intratracheal installation deli-
ver a large bolus of nanoparticles whereas normal inha-
lation delivers a much lower concentration of
nanoparticles per unit time.
Throughout this study, male rats were larger than
females (Tables 2 and 3, Figures 5A and 5B). There
appeared to be no consistent differences between male
and female in the organ content of gold and particularly
lung indicating that differences in were not likely to
have been due to a gender difference in deposition.
The higher accumulation of gold nanoparticles in the
kidneys found in the present study was also previously
observed in silver nanoparticle inhalation and oral expo-
sure studies [14,16], suggesting that the kidneys are the
major accumulation site for metal nanoparticles whether
the particles are ionized, like silver, or non-ionized, like
gold. Gender-related accumulation of gold nanoparticles
noted in this study was also observed for silver nanopar-
ticles in the inhalation and oral exposure studies [14,16].
It therefore appears that at least over the range of aver-
age nanoparticle sizes of 5 nm (gold, inhalation), 15-20
nm (silver, inhalation), and up to 60 nm (silver, oral)
there is a similar gender-related accumulation, and that
there is a difference in the pattern of nanoparticle distri-
bution between male and female kidneys. It is not
apparent whether this difference is anatomically or hor-
monally-based.
In contrast to the 0-hypothesis for silver suggested by
Wijnhoven et al. [38], in which silver toxicity mainly ori-
ginates from silver ions generated from the surface of
silver nanoparticles, the present results using gold nano-
particle inhalation provide a different view of nanoparti-
cle toxicity and distribution. Gold nanoparticles (1.4
nm) injected intravenously or administered by intratra-
cheal instillation are excreted into the urine and not
likely ionized in the body, they are translocated to tis-
sues as particles rather than in an ionic form [23]. This
implies that part or even a majority of the tissue distri-
bution pattern of silver nanoparticles could be due to
translocation in particulate form rather than ionic form
and that most of the silver captured in kidneys is not in
ionic form.
Currently, there are no occupational exposure stan-
dards for gold dust, fumes, or nanoparticles other than
general particulate standards such as the “particles not
otherwise regulated” standard of the US OSHA permis-
sible exposure limit (PEL) of 5 mg/m
3 for respirable par-
ticles. Changes observed in lung histopathology and
function in high-dose animals appear in and of them-
selves to be minor. In the previously reported study on
Sung et al. Particle and Fibre Toxicology 2011, 8:16
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Page 16 of 18silver nanoparticles, similar changes were noted [14] and
the authors interpreted them to be transient and not
sufficient to establish an effects level. It appears that our
original interpretation was not correct since when rats
from a recent 12 week exposure study similar to Sung
et al. [15] were allowed to “recover,” decreases in tidal
a n dm i n u t ev o l u m e sf r o mt h em i d d l ea n dh i g hd o s e
groups have persisted up to 12 weeks post-exposure
(unpublished data). In light of similar changes in this
study, it appears that the highest concentration (20 μg/
m
3) is a LOAEL and the middle concentration (0.38 μg/
m
3) as a NOAEL.
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